Literature DB >> 25793326

High within-day variability of fecal calprotectin levels in patients with active ulcerative colitis: what is the best timing for stool sampling?

Margalida Calafat1, Eduard Cabré, Míriam Mañosa, Triana Lobatón, Laura Marín, Eugeni Domènech.   

Abstract

BACKGROUND: Fecal calprotectin (FC) is considered the best noninvasive way to assess disease activity in ulcerative colitis (UC). However, it is not known which is the more suitable moment for stool sampling in patients with increased stool frequency. The aims of this study were to assess the intraindividual variation of FC within day and to evaluate if the first bowel movement in the morning is the more suitable sample for FC measurement in patients with acute flares of UC. PATIENTS AND METHODS: Patients admitted because of active UC were invited to collect samples from several bowel movements (including the first in the morning) during the same day providing their ordinal chronology. FC was measured by means of a quantitative rapid point-of-care test based on lateral flow assay immunochromatography.
RESULTS: Eighteen patients were included for a total of 56 stool samples. Most patients had extensive UC and severe disease activity. Within-day FC values varied widely, and the median coefficient of variation was 40% (5%-114%) with a median range of variation of FC values of 3887 mg/kg (69-9946). The sample from the first stool in the morning obtained the highest individual FC within-day value in 33.3% of cases and the lowest in 38.9%.
CONCLUSIONS: FC values widely vary between motions in patients with active UC. Stool sample collection from the first bowel movement in the morning does not ensure the highest or lowest within-day FC value. In patients with overt active UC, a single FC determination should not be used as the basis for therapeutic strategies.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25793326     DOI: 10.1097/MIB.0000000000000349

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  26 in total

Review 1.  Current best practice for disease activity assessment in IBD.

Authors:  Alissa J Walsh; Robert V Bryant; Simon P L Travis
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-09-01       Impact factor: 46.802

2.  Serial monitoring of faecal calprotectin for the assessment of endoscopic recurrence in asymptomatic patients after ileocolonic resection for Crohn's disease: a long-term prospective study.

Authors:  Takayuki Yamamoto; Takahiro Shimoyama; Satoru Umegae; Koichi Matsumoto
Journal:  Therap Adv Gastroenterol       Date:  2016-05-01       Impact factor: 4.409

Review 3.  Utility of surrogate markers for the prediction of relapses in inflammatory bowel diseases.

Authors:  Jason Orlando Dimitri Musci; Jack Stephen Cornish; Jan Däbritz
Journal:  J Gastroenterol       Date:  2016-03-14       Impact factor: 7.527

Review 4.  Disease monitoring in inflammatory bowel disease.

Authors:  Shannon Chang; Lisa Malter; David Hudesman
Journal:  World J Gastroenterol       Date:  2015-10-28       Impact factor: 5.742

Review 5.  How to predict clinical relapse in inflammatory bowel disease patients.

Authors:  Elisa Liverani; Eleonora Scaioli; Richard John Digby; Matteo Bellanova; Andrea Belluzzi
Journal:  World J Gastroenterol       Date:  2016-01-21       Impact factor: 5.742

6.  Association Between Fecal Calprotectin Levels and Small-bowel Inflammation Score in Capsule Endoscopy: A Multicenter Retrospective Study.

Authors:  Anastasios Koulaouzidis; Taina Sipponen; Artur Nemeth; Richard Makins; Uri Kopylov; Moshe Nadler; Andry Giannakou; Diana E Yung; Gabriele Wurm Johansson; Leonidas Bartzis; Henrik Thorlacius; Ernest G Seidman; Rami Eliakim; John N Plevris; Ervin Toth
Journal:  Dig Dis Sci       Date:  2016-03-23       Impact factor: 3.199

7.  Fecal calprotectin concentrations in cancer patients with Clostridium difficile infection.

Authors:  Taojun He; Samuel E Kaplan; Luz A Gomez; Xuedong Lu; Lakshmi V Ramanathan; Mini Kamboj; Yi-Wei Tang
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-09-21       Impact factor: 3.267

8.  Clinical significance of fecal calprotectin for the early diagnosis of abdominal type of Henoch-Schonlein purpura in children.

Authors:  Xu Teng; Cuiyun Gao; Mei Sun; Jie Wu
Journal:  Clin Rheumatol       Date:  2017-10-10       Impact factor: 2.980

9.  International consensus on methodological issues in standardization of fecal calprotectin measurement in inflammatory bowel diseases.

Authors:  Ferdinando D'Amico; David T Rubin; Paulo Gustavo Kotze; Fernando Magro; Britta Siegmund; Taku Kobayashi; Pablo A Olivera; Peter Bossuyt; Lieven Pouillon; Edouard Louis; Eugeni Domènech; Subrata Ghosh; Silvio Danese; Laurent Peyrin-Biroulet
Journal:  United European Gastroenterol J       Date:  2021-05-07       Impact factor: 4.623

10.  Serum Calprotectin: A Novel Diagnostic and Prognostic Marker in Inflammatory Bowel Diseases.

Authors:  Rahul Kalla; Nicholas A Kennedy; Nicholas T Ventham; Ray K Boyapati; Alex T Adams; Elaine R Nimmo; Micaela R Visconti; Hazel Drummond; Gwo-Tzer Ho; Rebecca J Pattenden; David C Wilson; Jack Satsangi
Journal:  Am J Gastroenterol       Date:  2016-09-06       Impact factor: 12.045

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.